NKure Therapeutics Partners with CRISPR Therapeutics for CAR T Therapy in India
Deal News | May 08, 2025 | Endiya Partners Ltd
NKure Therapeutics, an emerging biopharmaceutical company, has entered into a strategic partnership with CRISPR Therapeutics to co-develop CTX112™, a CRISPR-engineered cell therapy. This collaboration aims to address India's increasing cases of B-cell lymphomas by offering an off-the-shelf therapy that can be produced at scale, thereby overcoming the delays associated with current treatment options. The involvement of Endiya Partners, a notable private equity firm, highlights the potential market impact of making CAR T therapy more accessible and affordable in India.
Sectors
- Biotechnology
- Healthcare
- Private Equity
Geography
- India – The target market for the developed cell therapy is India, addressing the local burden of B-cell lymphomas.
- Switzerland – CRISPR Therapeutics is based in Switzerland, contributing to the geographic scope of the partnership.
Industry
- Biotechnology – The article discusses the development of CRISPR-engineered cell therapies, which are a product of biotechnological advancements.
- Healthcare – The focus is on providing new therapeutic solutions for B-cell lymphomas, thus falling under the healthcare sector.
- Private Equity – Endiya Partners, a private equity firm, plays a crucial role in backing the venture, emphasizing the private equity industry's involvement in innovation and healthcare.
Financials
- Not specified – The financial details of the collaboration and investment were not disclosed in the article.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| NKure Therapeutics | Target | Company | An emerging biopharmaceutical company in India focusing on cell therapy solutions. |
| CRISPR Therapeutics | Partner | Company | A biotechnology company based in Switzerland, known for its advancements in CRISPR technology. |
| Endiya Partners Ltd. | Investor | Company | A private equity firm providing financial backing to NKure Therapeutics for the development of new therapies. |